Dr. Greg Marchand Named to the Fulbright Specialist Roster by the U.S. Department of State
FOR IMMEDIATE RELEASE
MESA, Ariz. — December 22, 2022
Recently our researchers discovered some very novel practices being undertaken in China, where Uterine Artery Embolization (UAE), which is usually reserved for the treatment of Uterine Fibroids, is being used to treat Cesarean Scar Ectopic Pregnancies (CSP). We assembled the data we could find to offer this interesting look into these novel procedures taking place in China. The full paper is published online and can be viewed free of charge at the publisher’s website. the abstract can also be found on the US Government’s PubMed Website.
About Dr. Greg Marchand
Greg J. Marchand, MD, FACS, FACOG, FICS, is a dual board-certified obstetrician-gynecologist and minimally invasive gynecologic surgeon practising in Mesa, Arizona. He holds the ABOG Focused Practice Designation in Minimally Invasive Gynecologic Surgery and directs the Marchand Institute for Minimally Invasive Surgery, a 501(c)(3) tax-exempt non-profit research and educational corporation (EIN 42-2857240). He is Program Director of an SLS-accredited fellowship in Minimally Invasive and Robotic Gynecologic Surgery, holds three issued United States patents, and has served as Principal Investigator on eight FDA clinical trials. His systematic reviews are prospectively registered with PROSPERO, reported to PRISMA standards and appraised with the Cochrane Risk of Bias 2 tool. He accepts no industry funding for his research.
Media Contact
Maria A. Sainz
Director of Communications and Media Relations
maria@marchandobgyn.com
(480) 999-0905
Newsroom and press kit · Full publication list · Research methodology · Expert commentary topics
###
Related posts
